These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

669 related items for PubMed ID: 28806950

  • 1. Precision medicine approaches to lung adenocarcinoma with concomitant MET and HER2 amplification.
    Oh DY, Jung K, Song JY, Kim S, Shin S, Kwon YJ, Oh E, Park WY, Song SY, Choi YL.
    BMC Cancer; 2017 Aug 10; 17(1):535. PubMed ID: 28806950
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Clinical Utility of Patient-Derived Xenografts to Determine Biomarkers of Prognosis and Map Resistance Pathways in EGFR-Mutant Lung Adenocarcinoma.
    Stewart EL, Mascaux C, Pham NA, Sakashita S, Sykes J, Kim L, Yanagawa N, Allo G, Ishizawa K, Wang D, Zhu CQ, Li M, Ng C, Liu N, Pintilie M, Martin P, John T, Jurisica I, Leighl NB, Neel BG, Waddell TK, Shepherd FA, Liu G, Tsao MS.
    J Clin Oncol; 2015 Aug 01; 33(22):2472-80. PubMed ID: 26124487
    [Abstract] [Full Text] [Related]

  • 4. [Interest of crizotinib in a lung cancer patient with de novo amplification of MET].
    Rabeau A, Rouquette I, Vantelon JM, Taranchon-Clermont E, Mazières J.
    Rev Mal Respir; 2017 Jan 01; 34(1):57-60. PubMed ID: 27745897
    [Abstract] [Full Text] [Related]

  • 5. Acquired EGFR Mutation as the Potential Resistance Driver to Crizotinib in a MET-Mutated Tumor.
    Benderra MA, Aspeslagh S, Postel-Vinay S, Bigot L, De Baere T, Loriot Y, Lacroix L, Massard C, Vassal G, André F, Soria JC.
    J Thorac Oncol; 2016 Feb 01; 11(2):e21-3. PubMed ID: 26845121
    [No Abstract] [Full Text] [Related]

  • 6. Complete response to crizotinib in a patient with adenocarcinoma of the lung cancer harboring c- MET amplification.
    Cil I, Zirtiloglu A, Saydam N, Tural D.
    J BUON; 2017 Feb 01; 22(1):279-280. PubMed ID: 28365967
    [No Abstract] [Full Text] [Related]

  • 7. MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib.
    Lennerz JK, Kwak EL, Ackerman A, Michael M, Fox SB, Bergethon K, Lauwers GY, Christensen JG, Wilner KD, Haber DA, Salgia R, Bang YJ, Clark JW, Solomon BJ, Iafrate AJ.
    J Clin Oncol; 2011 Dec 20; 29(36):4803-10. PubMed ID: 22042947
    [Abstract] [Full Text] [Related]

  • 8. Responses to the multitargeted MET/ALK/ROS1 inhibitor crizotinib and co-occurring mutations in lung adenocarcinomas with MET amplification or MET exon 14 skipping mutation.
    Jorge SE, Schulman S, Freed JA, VanderLaan PA, Rangachari D, Kobayashi SS, Huberman MS, Costa DB.
    Lung Cancer; 2015 Dec 20; 90(3):369-74. PubMed ID: 26791794
    [Abstract] [Full Text] [Related]

  • 9. Detection of Crizotinib-Sensitive Lung Adenocarcinomas With MET, ALK, and ROS1 Genomic Alterations via Comprehensive Genomic Profiling.
    Le X, Freed JA, VanderLaan PA, Huberman MS, Rangachari D, Jorge SE, Lucena-Araujo AR, Kobayashi SS, Balasubramanian S, He J, Chudnovsky Y, Miller VA, Ali SM, Costa DB.
    Clin Lung Cancer; 2015 Sep 20; 16(5):e105-9. PubMed ID: 25922291
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Patient-derived xenografts from non-small cell lung cancer brain metastases are valuable translational platforms for the development of personalized targeted therapy.
    Lee HW, Lee JI, Lee SJ, Cho HJ, Song HJ, Jeong DE, Seo YJ, Shin S, Joung JG, Kwon YJ, Choi YL, Park WY, Lee HM, Seol HJ, Shim YM, Joo KM, Nam DH.
    Clin Cancer Res; 2015 Mar 01; 21(5):1172-82. PubMed ID: 25549722
    [Abstract] [Full Text] [Related]

  • 14. Responses to crizotinib in patients with ALK-positive lung adenocarcinoma who tested immunohistochemistry (IHC)-positive and fluorescence in situ hybridization (FISH)-negative.
    Ma D, Wang Z, Yang L, Mu X, Wang Y, Zhao X, Li J, Lin D.
    Oncotarget; 2016 Sep 27; 7(39):64410-64420. PubMed ID: 27418132
    [Abstract] [Full Text] [Related]

  • 15. An Anaplastic Lymphoma Kinase Immunohistochemistry-Negative but Fluorescence In Situ Hybridization-Positive Lung Adenocarcinoma Is Resistant to Crizotinib.
    Shi R, Varella-Garcia M, Li M, Ludkovski O, Danesh A, Ng C, Pham NA, Pugh T, Shepherd FA, Tsao MS.
    J Thorac Oncol; 2016 Dec 27; 11(12):2248-2252. PubMed ID: 27613526
    [Abstract] [Full Text] [Related]

  • 16. Response to Crizotinib in a Patient With Lung Adenocarcinoma Harboring a MET Splice Site Mutation.
    Jenkins RW, Oxnard GR, Elkin S, Sullivan EK, Carter JL, Barbie DA.
    Clin Lung Cancer; 2015 Sep 27; 16(5):e101-4. PubMed ID: 25769807
    [No Abstract] [Full Text] [Related]

  • 17. HER2, MET and FGFR2 oncogenic driver alterations define distinct molecular segments for targeted therapies in gastric carcinoma.
    Liu YJ, Shen D, Yin X, Gavine P, Zhang T, Su X, Zhan P, Xu Y, Lv J, Qian J, Liu C, Sun Y, Qian Z, Zhang J, Gu Y, Ni X.
    Br J Cancer; 2014 Mar 04; 110(5):1169-78. PubMed ID: 24518603
    [Abstract] [Full Text] [Related]

  • 18. Personalized Preclinical Trials in BRAF Inhibitor-Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies.
    Krepler C, Xiao M, Sproesser K, Brafford PA, Shannan B, Beqiri M, Liu Q, Xu W, Garman B, Nathanson KL, Xu X, Karakousis GC, Mills GB, Lu Y, Ahmed TA, Poulikakos PI, Caponigro G, Boehm M, Peters M, Schuchter LM, Weeraratna AT, Herlyn M.
    Clin Cancer Res; 2016 Apr 01; 22(7):1592-602. PubMed ID: 26673799
    [Abstract] [Full Text] [Related]

  • 19. Amplification of Wild-type KRAS Imparts Resistance to Crizotinib in MET Exon 14 Mutant Non-Small Cell Lung Cancer.
    Bahcall M, Awad MM, Sholl LM, Wilson FH, Xu M, Wang S, Palakurthi S, Choi J, Ivanova EV, Leonardi GC, Ulrich BC, Paweletz CP, Kirschmeier PT, Watanabe M, Baba H, Nishino M, Nagy RJ, Lanman RB, Capelletti M, Chambers ES, Redig AJ, VanderLaan PA, Costa DB, Imamura Y, Jänne PA.
    Clin Cancer Res; 2018 Dec 01; 24(23):5963-5976. PubMed ID: 30072474
    [Abstract] [Full Text] [Related]

  • 20. ALK inhibitors in the treatment of advanced NSCLC.
    Gridelli C, Peters S, Sgambato A, Casaluce F, Adjei AA, Ciardiello F.
    Cancer Treat Rev; 2014 Mar 01; 40(2):300-6. PubMed ID: 23931927
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 34.